PUBLISHER: DelveInsight Business Research LLP | PRODUCT CODE: 1064604
PUBLISHER: DelveInsight Business Research LLP | PRODUCT CODE: 1064604
DelveInsight's 'Chemotherapy-induced anemia - Market Insights, Epidemiology, and Market Forecast - 2032' report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of chemotherapy-induced anemia in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Chemotherapy-induced anemia market report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Chemotherapy-induced anemia market size from 2019 to 2032, segmented by seven major markets. The report also covers the current Chemotherapy-induced anemia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying market potential.
Study Period: 2019-2032
Chemotherapy-induced anemia Overview
Anemia is a frequent but insidious complication of cancer and its cytotoxic chemotherapy. According to the World Health Organization (WHO) definition, anemia occurs when hemoglobin (Hb) levels drop below 12 g/dL for women and 13 g/dL for men, and severity ranges from mild to severe or life-threatening. Anemia contributes to debilitating fatigue, lethargy, cardiovascular problems, shortness of breath, and reduced cognitive function in individuals who often already have significant morbidity and diminished quality of life (QOL) due to their malignancy.
When anemia occurs as an adverse event consequent to the toxic effect of anticancer treatment, it is called chemotherapy-induced anemia (CIA). The etiology of CIA is multifactorial; the primary causes are underlying cancer and the effects of chemotherapy. Anemia resulting from underlying cancer-known as the anemia of inflammation-causes cytokine release in the patient, leading to decreased erythropoietin production by the kidney, as well as restricted availability of iron. This process results in the condition known as functional iron deficiency. Anemia due to chemotherapy is often caused by myelosuppression. In addition, certain chemotherapeutic agents, especially platinum, can result in renal dysfunction, which can further decrease erythropoietin production. Chemotherapy regimens that contain cisplatin, used to treat lung and ovarian cancer, can be associated with significant anemia in 30% or more of treated patients. Chemotherapy agents such as docetaxel are also strongly associated with chemotherapy-induced anemia. Chemotherapy agents that are less myelosuppressive and less nephrotoxic are less likely to be associated with anemia.
Although CIA is one of the most common side effects of chemotherapy, it is often not recognized and is frequently undertreated. It can adversely affect long-term patient outcomes, as the anemic environment may limit the effectiveness of some chemotherapy agents. The incidence and severity of CIA depend on various factors, including the type, schedule, and intensity of therapy administered, or whether the patient has received prior myelosuppressive chemotherapy, radiation therapy, or both. An estimated 30-90% of cancer patients receiving chemotherapy develop anemia.
Correction of anemia can be achieved by either treating the underlying etiology or by providing supportive care that may entail transfusion with packed red blood cells (PRBCs) or administration of erythropoiesis-stimulating agents (ESAs), with or without iron supplementation. The first ESA approved by the US Food and Drug Administration (FDA) for treating anemia in patients receiving myelosuppressive chemotherapy was epoetin alfa, recombinant human erythropoietin (rhEpo). A second-generation rhEpo, darbepoetin alfa, has also been FDA-approved for this indication.
ESA's use has been a constant topic of debate. Despite the clinical benefit of ESAs for CIA, both randomized clinical studies and systematic reviews demonstrated a significantly higher risk of thromboembolic events in patients receiving ESAs for CIA.
Efforts should be made to identify the etiology of anemia, and treatment should be directed to the underlying cause. However, identifying a specific causative factor can occasionally be difficult, and directed therapeutic intervention may not be effective.
Chemotherapy-induced anemia Diagnosis and Treatment
It covers the details of conventional and current medical therapies and diagnoses available in the Chemotherapy-induced anemia market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.
The DelveInsight Chemotherapy-induced anemia Market Report gives a thorough understanding of chemotherapy-induced anemia by including details of disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides the treatment algorithms and treatment guidelines for Chemotherapy-induced anemia in the US, Europe, and Japan.
The Chemotherapy-induced anemia epidemiology division provides insights into the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed incident patient pool, trends, and assumptions.
The disease epidemiology covered in the report provides historical and forecasted Chemotherapy-induced anemia epidemiology segmented as the Incidence of chemotherapy-induced anemia, severity-specific cases of chemotherapy-induced anemia, and Incidence of chemotherapy-induced anemia per chemo cycles. The report includes the incident scenario of Chemotherapy-induced anemia symptoms in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
The epidemiology segment also provides the Chemotherapy-induced anemia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The incident Chemotherapy-induced anemia population in the 7MM countries was estimated to be ~1.6 million cases in 2021.
The drug chapter segment of the Chemotherapy-induced anemia report encloses the detailed analysis of Chemotherapy-induced anemia marketed drugs and late stage (Phase-III, Phase-II/III, Phase-II, and Phase-I/II) pipeline drugs. It also helps to understand the Chemotherapy-induced anemia clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Correction of anemia can be achieved by either treating the underlying etiology or by providing supportive care that may entail transfusion with packed red blood cells (PRBCs) or administration of erythropoiesis-stimulating agents (ESAs), with or without iron supplementation. The decision regarding the best treatment is dependent on many factors. While PRBC transfusion is the only option if the patient requires an immediate boost in Hb levels, consideration of ESA therapy and iron supplementation may be warranted for the long-term management of anemia as determined by risk assessment.
Products detail in the report…
Chemotherapy-induced anemia Emerging Drugs
Roxadustat (FG-4592), an oral medication, is the first in a new class of medicines comprising hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin. Roxadustat has been approved in European Union (EU) member states, including the European Economic Area (EEA) countries, as well as in Japan, China, Chile, and South Korea for the treatment of anemia of CKD in adult patients on dialysis (DD) and not on dialysis (NDD).
The drug has completed its evaluation in Phase II in patients with CIA. Roxadustat is also in clinical development for anemia of chronic kidney disease (CKD) and anemia associated with myelodysplastic syndromes (MDS).
Products detail in the report…
The Chemotherapy-induced anemia market outlook of the report builds a detailed comprehension of the historical, current, and forecasted Chemotherapy-induced anemia market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of the Chemotherapy-induced anemia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Chemotherapy-induced anemia market in the 7MM is expected to change in the study period 2019-2032.
Currently, different short- and long-acting formulations of ESAs are available. The first ESA was approved by the US FDA for the treatment of anemia in patients receiving myelosuppressive chemotherapy as epoetin alfa (Epogen/ Procrit), recombinant human erythropoietin (rhEpo). A second-generation rhEpo, darbepoetin alfa (Aranesp), has also been FDA-approved for this indication. After their approval for the CIA, their use expanded tremendously (Bloudek & Carlson, 2021).
Several biosimilar epoetin options have become accessible since the patent expiration of epoetin alfa. The FDA recently approved the biosimilar for treating anemia, epoetin alfa-epbx (Retacrit). It was launched at a 33.5% discount to reference Epogen.
This section includes a glimpse of the Chemotherapy-induced anemia market in the 7MM. The market size of chemotherapy-induced anemia in the seven major markets was over USD 1 billion in 2021.
This section provides the total Chemotherapy-induced anemia market size and market size by therapies of Chemotherapy-induced anemia in the United States.
The United States accounts for the highest market size of chemotherapy-induced anemia compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
In order to cater to the current unmet needs in the CIA treatment, Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors have emerged as a new class of orally-administered agents for the management of anemia in chemotherapy. They induce considerably lower but more consistent erythropoietin levels than ESAs, and it has been hypothesized that they could cause fewer adverse cardiovascular events than ESAs.
The pipeline for CIA is currently limited, consisting of only one key asset, i.e., roxadustat, the HIF-PH inhibitor, which has completed its investigation in Phase II in 2021. Other assets in development include ALRN-6924 and Desidustat.
To conclude, with growing cancer cases, the incidence of CIA is likely to increase in the coming years, escalating the need for treatment. Thus, more clinical studies to bring novel treatment are needed to address the unmet needs in the treatment of anemia in cancer patients receiving chemotherapy.
The total Chemotherapy-induced anemia market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are also mentioned.
The total Chemotherapy-induced anemia market size and market size by therapies of Chemotherapy-induced anemia in Japan are also mentioned.
This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2019-2032. The analysis covers Chemotherapy-induced anemia market uptake by drugs, patient uptake by therapies, and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.
Chemotherapy-induced anemia Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, Phase II/III, Phase II, and Phase I/II stage. It also analyses chemotherapy-induced anemia's key players involved in developing targeted therapeutics.
Major players include Astellas/FibroGen/AstraZeneca, Aileron Therapeutics and Zydus Cadila, and others, whose key products are expected to get launched in the US market by 20XX.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing, and patent details for Chemotherapy-induced anemia emerging therapies.
To keep up with current market trends, we take KOLs and SMEs' opinions working in the Chemotherapy-induced anemia domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Chemotherapy-induced anemia market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform a Competitive and Market Intelligence analysis of the Chemotherapy-induced anemia market using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies: